The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate
Abstract
Background: The aim of the study was to analyze the surgical possibilities of unresectable and/or metastatic GIST CD117(+) patients during imatinib treatment. Methods: We analyzed the results of surgery in 141 patients treated with imatinib for initially inoperable and/or metastatic GIST CD117(+). Median follow‐up time was 12 months (range: 3–26). Results: Surgery was performed as subsequent treatment in 24 patients (Group I, 17%) for resection of residual disease after complete/partial response and lack of further response to imatinib and as salvage therapy in eight patients (Group II, 6%), who progressed on initially successful imatinib therapy. In Group I, the viable GIST cells were not detected histologically in only three resection specimens. The first five patients in Group I did not receive imatinib further and we observed four recurrences. In next 19 patients, continuing imatinib after surgery, we observed only one relapse. In Group II, we continued imatinib therapy after high‐risk surgical procedures, but in five patients we observed subsequent progression. Conclusions: Surgical removal of residual disease during imatinib treatment may allow for complete remission in selected GIST patients after response to therapy, theoretically prolonging durable remission, but it is necessary to continue imatinib for its maintenance. J. Surg. Oncol. 2006;93:304–311. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Cited by
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0116 · Cited by 1,219
Demetri, G. D., Benjamin, R. S., Blanke, C. D., Blay, J.-Y., Casali, P., Choi, H., Corless, C. L., Debiec-Rychter, M., DeMatteo, R. P., Ettinger, D. S., et al. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.2002 · Cited by 634
Eisenberg, B. L., Harris, J., Blanke, C. D., Demetri, G. D., Heinrich, M. C., Watson, J. C., Hoffman, J. P., Okuno, S., Kane, J. M., & von Mehren, M. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21160 · Cited by 427
Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version
Nishida, T., Hirota, S., Yanagisawa, A., Sugino, Y., Minami, M., Yamamura, Y., Otani, Y., Shimada, Y., Takahashi, F., & Kubota, T. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0798-7 · Cited by 353
Yoshida, K., Yamaguchi, K., Okumura, N., Tanahashi, T., & Kodera, Y. (2016) · Gastric Cancer · doi:10.1007/s10120-015-0575-z · Cited by 350
Metadata
- Authors
- Rutkowski, P., Nowecki, Z., Nyckowski, P., Dziewirski, W., Grzesiakowska, U., Nasierowska‐Guttmejer, A., Krawczyk, M., & Ruka, W.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2006-02-22
- Volume
- 93
- Issue
- 4
- Pages
- 304-311
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2012444260
- Cited by
- 187
- References
- 1
- FWCI
- 16.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.